Last reviewed · How we verify
colimycin
colimycin is a Small molecule drug developed by Poitiers University Hospital. It is currently in Phase 1 development for Enterobacter Infection, Infection due to Escherichia coli, Klebsiella Infections.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | colimycin |
|---|---|
| Sponsor | Poitiers University Hospital |
| Target | Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Approved indications
- Enterobacter Infection
- Infection due to Escherichia coli
- Klebsiella Infections
- Mastoidectomy Cavity Infections
- Otitis externa
- Pseudomonas Aeruginosa Infections
Common side effects
Key clinical trials
- Incidence of Infection After Total Knee Arthroplasty Using an Erythromycin and Colistin Loaded Cement or a Standard Cement (NA)
- Prospective Observational Study, Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection (N/A)
- A Multicenter, Open-label, Randomized, Active-controlled, Parallel Group, Pivotal Study to Investigate the Efficacy, Safety and Tolerability, and Pharmacokinetics of Murepavadin Combined With One Anti (Phase 3)
- Pharmacokinetics and Pharmacodynamics of Intravenous Colistin- Pilot Study (NA)
- Evaluation of Ceftazidime-avibactam Plus Aztreonam in Patients Infected by MBL-producing Enterobacterales and CRISPR/Cas9-based Strategy for Curing Drug-resistant Genes (NA)
- A Study to Compare 7-days Versus 14 Days of Antibiotics Therapy for Ventilator Associated Pneumonia Due to Drug Resistant Acinetobacter Baumanii (NA)
- NCT02573064 (N/A)
- Randomized, Double-blind, Parallel-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Polymyxin E2 Mesylate Intravenous Infusion Combined With Nebulized Inhalation (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- colimycin CI brief — competitive landscape report
- colimycin updates RSS · CI watch RSS
- Poitiers University Hospital portfolio CI
Frequently asked questions about colimycin
What is colimycin?
What is colimycin used for?
Who makes colimycin?
What development phase is colimycin in?
What does colimycin target?
Related
- Target: All drugs targeting Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor
- Manufacturer: Poitiers University Hospital — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Enterobacter Infection
- Indication: Drugs for Infection due to Escherichia coli
- Indication: Drugs for Klebsiella Infections
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing